The NeoLSD™ MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-β-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid α glucosidase (GAA), β galactocerebrosidase (GALC), α-galactosidase A (GLA) and α-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Products may not be licensed in accordance with their laws in all countries, such as Canada. Please check with your local representative for availability.
The first commercial IVD kit for newborn screening of Pompe, MPS-I, Fabry, Gaucher, Niemann-Pick A/B and Krabbe disorders from a single DBS sample.
Due to advancements in treatments of lysosomal storage disorders and the subsequently increasing demand for newborn screening of these disorders, we are proud to release the NeoLSD MSMS Kit, the first commercial mass spectrometry based IVD kit for newborn screening of up to six lysosomal storage disorders from a single blood spot punch. The analysis of the enzymatic activity is intended as an aid in screening newborns for the following lysosomal storage disorders respectively; Gaucher Disease, Niemann-Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and MPS I Disease.
The NeoLSD MSMS kit enables running up to 500 tests per instrument per day and easily switching between NeoBase™ 2 and NeoLSD™ kits on a single MSMS instrument. In addition, the NeoLSD kit provides you a wide analytical range, leading to potentially lower false positive rates, less costs associated with repeat enzyme activity tests and molecular testing.
The Benefits of the assay are as below:
The kit includes all necessary for effective LSD newborn screen. It comes equipped with 3 packages.
|Detection Method||Mass Spectrometry (MSMS)|
|Disorders||Niemann-Pick A/B, Gaucher, Krabbe, Fabry, Pompe, MPS-I|
|Product Brand Name||NeoLSD™, MSMS Kit|
|Unit Size||1 Kit|